INDEGENE LIMITED
Latest filings
Next results: Thu, 29 Oct · Financial Results- Indegene incorporates wholly owned Portugal subsidiary · Strategic Transactions
- Indegene earns global recognition for AI-powered pharma commercialization · Compliance
- Non-Executive Director Mark Dzialga resigns effective October 29, 2026 · Management Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Provides AI-embedded commercial and medical outsourcing services to global life sciences companies, particularly large pharmaceutical firms. Enterprise Commercial Solutions, which contributed 70.1% of segment revenue at ₹2,460.5 crore in FY26, handles sales, marketing and omnichannel engagement work for pharma clients. Enterprise Medical Solutions, contributing 26.5% at ₹929.8 crore, covers medical affairs, scientific content and clinical communications. The company serves 20 of the Top 20 global pharma companies and 80 of the Top 100 life sciences firms, with an active client base that grew from 73 to 91 in FY26 and reached 105 by Q1 FY27. Employee costs are the dominant input at 62.6% of revenue, reflecting a delivery model built on specialised healthcare and technology talent rather than physical inputs. The company reports 98.47% export revenue, operates across 58 countries and runs 5,167 employees, with revenue per employee at approximately $77,000.
Scorecard
Measured from the filed financials, judged against its Healthcare Services peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from INDEGENE LIMITED's filed financials and exchange disclosures
What does INDEGENE LIMITED do?
INDEGENE LIMITED is a Healthcare Services company listed on NSE and BSE, trading under the symbol INDGN.
Is INDEGENE LIMITED profitable?
Yes. Over the trailing twelve months INDEGENE LIMITED reported a net profit of ₹401 Cr on revenue of ₹3,813 Cr.
Does INDEGENE LIMITED pay a dividend?
Yes. The dividend yield is 0.33% at the current price. It paid out 12% of its profit as dividend in FY26.
Is INDEGENE LIMITED debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹301 Cr of cash.
Is INDEGENE LIMITED expensive compared with its peers?
On trailing P/E, INDEGENE LIMITED ranks 33 of 63 in Healthcare Services — cheaper than 48% of them, against an industry median of 35.6×. This is a position, not a valuation judgement.
How much does the INDEGENE LIMITED share price move in a day?
On a typical session INDEGENE LIMITED moves 0.96% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are INDEGENE LIMITED's next results?
Financial Results on Thu, 29 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track INDEGENE LIMITED's announcements?
Every NSE and BSE filing by INDEGENE LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.